Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
View Patent ↗This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.
1. An isolated antibody that binds to a human IFN-γ, comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, or SEQ ID NO:30 and/or the amino acid sequence of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, or SEQ ID NO:31.
2. The antibody of claim 1 , comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, or SEQ ID NO:30.
3. The antibody of claim 2 , further comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, or SEQ ID NO:31.
4. The antibody of claim 3 , comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, or SEQ ID NO:31.
5. The antibody of claim 2 , further comprising an amino acid sequence which comprises:
the amino acid sequence of SEQ ID NO:38, SEQ ID NO:39, or SEQ ID NO:40;
the amino acid sequence of SEQ ID NO:41 or SEQ ID NO:42; and
the amino acid sequence of SEQ ID NO:43 or SEQ ID NO:44.
6. The antibody of claim 3 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:8.
7. The antibody of claim 3 , comprising an amino acid sequence at least 95% identical to SEQ ID NO: 12 .
8. The antibody of claim 3 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:16.
9. The antibody of claim 3 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:31.
10. The antibody of claim 1 , comprising the amino acid sequence of SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, or SEQ ID NO:31.
11. The antibody of claim 10 , further comprising an amino acid sequence at least 95% identical to SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, or SEQ ID NO:30.
12. The antibody of claim 11 , comprising an amino acid sequence at least 98% identical to SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, or SEQ ID NO:30.
13. The antibody of claim 10 , further comprising an amino acid sequence which comprises:
the amino acid sequence of SEQ ID NO:34;
the amino acid sequence of SEQ ID NO:35; and
the amino acid sequence of SEQ ID NO:36 or SEQ ID NO:37.
14. The antibody of claim 11 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:6.
15. The antibody of claim 11 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:10.
16. The antibody of claim 11 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:4.
17. The antibody of claim 11 , comprising an amino acid sequence at least 95% identical to SEQ ID NO:30.
18. The antibody of claim 2 , further comprising the amino acid sequence of SEQ ID NO:8.
19. The antibody of claim 2 , further comprising the amino acid sequence of SEQ ID NO:12.
20. The antibody of claim 2 , further comprising the amino acid sequence of SEQ ID NO:16.
21. The antibody of claim 2 , further comprising the amino acid sequence of SEQ ID NO:31.
22. The antibody of claim 10 , further comprising the amino acid sequence of SEQ ID NO:6.
23. The antibody of claim 10 , further comprising the amino acid sequence of SEQ ID NO:10.
24. The antibody of claim 10 , further comprising the amino acid sequence of SEQ ID NO:14.
25. The antibody of claim 10 , further comprising the amino acid sequence of SEQ ID NO:30.
26. The antibody of claim 13 , comprising SEQ ID NO:36.
27. A composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody of claim 2 .
28. A composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody of claim 10 .
29. A composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody of claim 3 .